Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.
作者信息
Jones David R, Wu Yi-Long, Tsuboi Masahiro, Herbst Roy S
机构信息
Thoracic Service, Department of Surgery, and Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong, China.
出版信息
J Thorac Cardiovasc Surg. 2021 Jul;162(1):288-292. doi: 10.1016/j.jtcvs.2021.02.008. Epub 2021 Feb 9.
Abstract
摘要
相似文献
1
Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.可切除肺腺癌的靶向治疗：ADAURA研究为胸外科肿瘤医生带来新契机
J Thorac Cardiovasc Surg. 2021 Jul;162(1):288-292. doi: 10.1016/j.jtcvs.2021.02.008. Epub 2021 Feb 9.
2
Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.奥希替尼治疗双EGFR L747S和G719C突变患者的临床疗效
J Thorac Oncol. 2019 Jul;14(7):e151-e153. doi: 10.1016/j.jtho.2019.02.034.
3
Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.在一名患有EGFR L718Q突变的非小细胞肺癌患者中使用阿法替尼解决对奥希替尼治疗的耐药性
Clin Lung Cancer. 2020 Jul;21(4):e258-e260. doi: 10.1016/j.cllc.2019.12.002. Epub 2020 Jan 23.
4
Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.通过循环肿瘤DNA分析对接受奥希替尼治疗的表皮生长因子受体（EGFR）突变型肺腺癌患者的多种耐药机制进行早期检测
Clin Lung Cancer. 2020 Sep;21(5):e488-e492. doi: 10.1016/j.cllc.2020.03.009. Epub 2020 Apr 9.
5
Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma.卡马替尼与奥希替尼联合治疗EGFR突变型肺腺癌
J Thorac Oncol. 2020 Jan;15(1):e13-e15. doi: 10.1016/j.jtho.2019.07.027.
6
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.奥希替尼治疗可切除突变型非小细胞肺癌。
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
7
Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report.肺腺癌脑脊液中脑膜转移的检测：病例报告
Clin Lung Cancer. 2020 Sep;21(5):e493-e496. doi: 10.1016/j.cllc.2020.04.010. Epub 2020 Apr 15.
8
Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.携带EGFR突变和BRAF V600E的肺腺癌对奥希替尼和维莫非尼联合用药有反应，可克服奥希替尼耐药性。
Clin Lung Cancer. 2021 May;22(3):e390-e394. doi: 10.1016/j.cllc.2020.06.008. Epub 2020 Jun 11.
9
Segmentectomy of the left superior segment (S) 4 years after segmentectomy of the left dorsobasal segment (S).
J Thorac Cardiovasc Surg. 2018 Mar;155(3):1302-1304. doi: 10.1016/j.jtcvs.2017.08.119. Epub 2017 Sep 13.
10
Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.一名患有罕见表皮生长因子受体（EGFR）突变的肺腺癌患者在对奥希替尼产生获得性耐药后发生鳞状细胞癌转化。
J Formos Med Assoc. 2020 Sep;119(9):1439-1441. doi: 10.1016/j.jfma.2019.12.017. Epub 2020 Mar 12.
引用本文的文献
1
Mechanism of action for Troxerutin targeting the sialylation-related gene EGLN3 for the treatment of LUAD.曲克芦丁靶向唾液酸化相关基因EGLN3治疗肺腺癌的作用机制。
Sci Rep. 2025 Mar 18;15(1):9298. doi: 10.1038/s41598-025-92028-2.
2
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.非小细胞肺癌中的分子通路、耐药机制及靶向干预
Mol Biomed. 2022 Dec 12;3(1):42. doi: 10.1186/s43556-022-00107-x.
3
A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting c-fos.BRMS1 中的种系 SNP 使肺腺癌患者易发生转移，并可通过靶向 c-fos 加以改善。
Sci Transl Med. 2022 Oct 5;14(665):eabo1050. doi: 10.1126/scitranslmed.abo1050.
4
Targeted Therapy in Early Stage Non-small Cell Lung Cancer.早期非小细胞肺癌的靶向治疗。
Curr Treat Options Oncol. 2022 Sep;23(9):1169-1184. doi: 10.1007/s11864-022-00994-w. Epub 2022 Jul 25.
5
Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France).建立一种超快速下一代测序方法作为非鳞状非小细胞肺癌诊断时的补充检测；单中心（法国尼斯市LPCE）的经验
Cancers (Basel). 2022 Apr 30;14(9):2258. doi: 10.3390/cancers14092258.
本文引用的文献
1
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.吉非替尼对比长春瑞滨联合顺铂用于 II-IIIA 期（N1-N2）表皮生长因子受体突变型非小细胞肺癌的辅助治疗：CTONG1104 期 III 临床试验最终总生存分析。
J Clin Oncol. 2021 Mar 1;39(7):713-722. doi: 10.1200/JCO.20.01820. Epub 2020 Dec 17.
2
Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.ADAURA辅助性抗癌药物试验的经验教训：证据、伦理与经济学
J Clin Oncol. 2021 Jan 20;39(3):175-177. doi: 10.1200/JCO.20.01762. Epub 2020 Dec 4.
3
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.奥希替尼治疗可切除突变型非小细胞肺癌。
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
4
The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer.国际肺癌研究协会肺癌分子检测全球调查。
J Thorac Oncol. 2020 Sep;15(9):1434-1448. doi: 10.1016/j.jtho.2020.05.002. Epub 2020 May 20.
5
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
6
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.选择：表皮生长因子受体突变型非小细胞肺癌患者术后辅助厄洛替尼的 II 期临床试验。
J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16.
7
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
8
Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer.循环肿瘤DNA：一种指导非小细胞肺癌术后治疗和监测的有前景的生物标志物。
J Thorac Cardiovasc Surg. 2018 Jun;155(6):2628-2631. doi: 10.1016/j.jtcvs.2017.12.157. Epub 2018 Mar 13.
9
Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma.R0 肺叶切除术后 pN0 肺腺癌远处复发的相关因素。
J Thorac Cardiovasc Surg. 2018 Mar;155(3):1212-1224.e3. doi: 10.1016/j.jtcvs.2017.09.151. Epub 2017 Nov 13.
10
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.吉非替尼对比长春瑞滨联合顺铂作为 EGFR 突变型 II-IIIA 期（N1-N2）可切除 NSCLC（ADJUVANT/CTONG1104）的辅助治疗：一项随机、开放标签、III 期研究。
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
Zotero 插件